Mereo BioPharma Group plc(MREO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,916 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
MREO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Mereo BioPharma Group plc (MREO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MREO at 9.4/100 on a 32-signal composite quality model, placing it at rank #2,916 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Mereo BioPharma Group plc reports net income of $-7.0M, free cash flow of $-6.0M. Top institutional holders of MREO by reported 13-F value include Rubric Capital Management, 683 Capital Management, BANK OF AMERICA, based on the most recent SEC filings. MREO trades on the Nasdaq exchange and files with the SEC under CIK 1719714. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MREO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mereo BioPharma Group plc directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-7.0M
Free Cash Flow
Q2 2026
$-6.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+3.2% YoYOperating Income
+15.3% YoYEPS (Diluted)
+16.7% YoYTotal Assets
-39.9% YoYOp. Cash Flow
+5.7% YoYFree Cash Flow
+5.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $500.0K | $0.00 -100.0% | $10.0M | $0.00 -100.0% | $36.5M | — |
| Net Income | $-41.9M +3.2% | $-43.3M -46.8% | $-29.5M +30.2% | $-42.2M | — | — |
| Operating Income | $-40.1M +15.3% | $-47.4M -66.7% | $-28.4M +47.8% | $-54.4M | — | — |
| EPS (Diluted) | $-0.05 +16.7% | $-0.06 -50.0% | $-0.04 +42.9% | $-0.07 | — | — |
| Total Assets | $45.9M -39.9% | $76.4M +14.9% | $66.5M -14.1% | $77.4M -38.8% | $126.4M +100.8% | $62.9M |
| Operating Cash Flow | $-31.0M +5.7% | $-32.8M -55.4% | $-21.1M +56.7% | $-48.8M | — | — |
| Free Cash Flow | $-31.0M +5.6% | $-32.8M -55.4% | $-21.1M +56.7% | $-48.8M | — | — |
Get alerted when MREO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Mereo BioPharma Group plc including:
Top Institutional Holders of MREO
Rubric Capital Management LP
$4.9M15,307,347 sh683 Capital Management, LLC
$3.7M11,777,856 shBANK OF AMERICA CORP /DE/
$2.6M8,195,281 shDefilade Capital Management, L.P.
$2.4M7,558,756 shNewtyn Management, LLC
$953.1K3,000,000 shTejara Capital Ltd
$647.3K2,037,520 shUBS Group AG
$460.3K1,447,627 shTWO SIGMA INVESTMENTS, LP
$419.1K1,319,241 shEcoR1 Capital, LLC
$317.7K1,000,000 shJANE STREET GROUP, LLC
$246.2K774,944 sh
| Fund | Value | Shares |
|---|---|---|
| Rubric Capital Management LP | $4.9M | 15,307,347 |
| 683 Capital Management, LLC | $3.7M | 11,777,856 |
| BANK OF AMERICA CORP /DE/ | $2.6M | 8,195,281 |
| Defilade Capital Management, L.P. | $2.4M | 7,558,756 |
| Newtyn Management, LLC | $953.1K | 3,000,000 |
| Tejara Capital Ltd | $647.3K | 2,037,520 |
| UBS Group AG | $460.3K | 1,447,627 |
| TWO SIGMA INVESTMENTS, LP | $419.1K | 1,319,241 |
| EcoR1 Capital, LLC | $317.7K | 1,000,000 |
| JANE STREET GROUP, LLC | $246.2K | 774,944 |
More Healthcare Companies
View all Healthcare →Put MREO on your watchlist
Track score changes the day Mereo BioPharma Group plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MREO a good stock to buy?
13F Pro's AI-powered analysis of Mereo BioPharma Group plc (MREO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MREO are available on the MREO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MREO is classified as a small company.
Which hedge funds own MREO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MREO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mereo BioPharma Group plc's investment landscape.